西格列汀联合大剂量胰岛素治疗2型糖尿病的临床观察

doi:10.6040/j.issn.1671-7554.0.2014.747

摘要/Abstract

摘要： 目的观察大剂量胰岛素联合西格列汀治疗2型糖尿病的临床疗效和安全性.方法选取2012年9月至2013年9月确诊2型糖尿病并需大剂量胰岛素(>60 U/d)治疗的患者60例,随机分为两组:胰岛素+西格列汀组(胰岛素>60 U/d,西格列汀100 mg,1次/d)和胰岛素组(胰岛素>60 U/d),每组30例.治疗3个月,根据血糖情况调整剂量.比较治疗前及治疗3个月后血糖、血脂等指标的变化及两组间主要指标的变化情况.结果治疗3个月后,两组空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)较治疗前有所下降(P均<0.05),胰岛素组胰岛素用量及体质量指数(BMI)较治疗前显著增加(P<0.05),胰岛素+西格列汀组治疗后胰岛素用量减少,BMI、甘油三酯(TG)降低(P<0.05).胰岛素组与胰岛素+西格列汀组胰岛素用量[(70.32±6.56) vs (59.26±5.03)U]、TG[(2.64±1.32) vs (2.21±0.92)mmol/L]、BMI(27.24±2.36 vs 26.25±1.92)差异具有统计学意义(P均<0.01).胰岛素组与胰岛素+西格列汀组分别有8例(26.70%)和1例(3.30%)患者出现低血糖.结论大剂量胰岛素(>60 U/d)联合西格列汀(100 mg,1次/d)治疗2型糖尿病有利于患者血糖、血脂、BMI的控制,同时可以减少胰岛素用量,降低低血糖发生率.

关键词: 西格列汀, 低血糖, 2型糖尿病, 大剂量胰岛素

Abstract: Objective To observe the efficacy and safety of sitagliptin combined with high-dose insulin on type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes who needed high-dose insulin(greater than 60 U/d) treatment, diagnosed during Sep. 2012 to Sep. 2013 in our hospital, were divided into insulin combined with sitagliptin group(insulin>60 U/d and sitagliptin 100 mg 1 time/d) and insulin group (insulin>60 U/d ), with 30 patients in each group. After 3-month treatment, the levels of blood glucose, serum lipid and other indicators were compared between the two groups. Results After 3-month treatment, fasting blood glucose(FBG), 2-hour postprandial glucose (2hPG), glycosylated hemoglobin(HbA1c) decreased significantly (all P<0.05) in both group. The insulin dosage, body mass index (BMI) increased significantly (P<0.05) after treatment in insulin group, while the insulin dosage, BMI and triglyceride(TG)reduced significantly (P<0.05) after treatment in insulin combined with sitagliptin group. Compared with insulin group, the patients in insulin combined with sitagliptin group showed lower insulin dosage[(70.32±6.56) vs (59.26±5.03)U], TG[(2.64±1.32) vs (2.21±0.92) mmol/L] and BMI (27.24±2.36 vs 26.25±1.92)(all P<0.01). One patient(3.30%)in insulin combined with sitagliptin group and 8 patients (26.70%) in insulin group occurred hypoglycemia. Conclusion Sitagliptin(100 mg, 1 time/d) combined with high-dose(>60 U/d)insulin in the therapy of patients with type 2 diabetes mellitus is beneficial for controlling the indicators, such as blood glucose, serum lipid, BMI as well as reducing the dosage of insulin and occurrence of hypoglycemia.

Key words: Type 2 diabetes mellitus, High-dose insulin, Low blood glucose, Sitagliptin

中图分类号:

R587.1

裴蕾蕾, 孙中华, 李哲, 赵文萍. 西格列汀联合大剂量胰岛素治疗2型糖尿病的临床观察[J]. 山东大学学报（医学版）, 2015, 53(2): 39-42.

PEI Leilei, SUN Zhonghua, LI Zhe, ZHAO Wenping. Effects of sitagliptin combined with high-dose insulin on type 2 diabetes mellitus[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 39-42.

参考文献

[1] International Diabetes Federation. IDF Diabetes Atlas, sixth edition[EB/OL].[2014-09-20]. http://www.idf.org/diabetesatlas/.
[2] 中华医学会糖尿病学分会.2013年中国2型糖尿病防治指南[J].中华糖尿病杂志,2014,6(7):447-498.
[3] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12):1090-1101.
[4] 李晓赟,董吉祥,谢莹. 磷酸西格列汀联合胰岛素治疗2型糖尿病疗效观察[J]. 中国现代医药杂志,2012,14(9):36-37. LI Xiaoyun, DONG Jixiang, XIE Ying. Effect observation on treatment of type 2 diabetes with sitagliptin phosphate tablets and insulin[J]. Modern Medicine Journal of China, 2012, 14(9):36-37.
[5] 刘海岩.糖尿病的脂代谢紊乱及其治疗[J].实用糖尿病杂志,2005,1(4):51-53.
[6] Kojima Y, Kaga H, Hayashi S, et al. Comparison between sitagliptin and nateglinide on postprandial lipid levels:the STANDARD study[J]. World J Diabetes, 2013, 4(1):8-13.
[7] Hidekatsu Y, Hiroki A, Hidetaka H, et al. Effects of 6-Month Sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 Diabetic patients: a chart-based analysis[J]. J Clin Med Res, 2012, 4(4):251-258.
[8] Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and Meta-analysis[J]. Adv Ther, 2012, 29(1):14-25.
[9] 陆菊明. 中国2型糖尿病防治指南(2013年版)更新要点的解读[J]. 中国糖尿病杂志,2014,22(10):865-869. LU Juming. Updated key points of 2013 China guideline for type 2 diabetes[J]. Chinese Journal of Diabetes, 2014, 22(10):865-869.
[10] 龚健,胡欣,张峰. 西格列汀联合甘精胰岛素治疗老年2型糖尿病的临床观察[J]. 中华保健医学杂志,2013,15(2):175,185.
[11] Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes:a randomized,double-blind,placebo-controlled trial[J]. Curr Med Res Opin, 2011, 27(5):1049-1058.
[12] Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes[J]. N Engl J Med, 2007, 357(17):1716-1730.
[13] Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanase patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2008, 79(2):291-298.
[14] Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2010, 12(3):252-261.
[15] Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study[J]. Diabetes Obes Metab, 2012, 14(9):795-802.
[16] Miura Y, Matsui H. TriphenyItin impairs a protein kinase A(PKA)-dependent increase of cytosolic Na⁺ and Ca²⁺ and PKA-independent increase of cytosolic Ca⁺ associated with insulin secretion in hamster pancreatic beta-cell[J].Toxicol Appl Pharmacol, 2006, 216(3):363-372.
[17] Lee YS, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis[J]. Diabetes, 2007, 56(6):1671-1679.

相关文章 15

[1]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[2]	苏萍,杨亚超,杨洋,季加东,阿力木·达依木,李敏,薛付忠,刘言训. 健康管理人群2型糖尿病发病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 82-86.
[3]	李帅,王雅琳,孙忠文,朱梅佳. Nod样受体蛋白3炎性体在2型糖尿病脑微血管内皮细胞中的变化及变化机制[J]. 山东大学学报（医学版）, 2017, 55(3): 6-11.
[4]	杨洋,张光,张成琪,宋心红,薛付忠,王萍,王丽,刘言训. 基于体检队列的2型糖尿病风险预测模型[J]. 山东大学学报（医学版）, 2016, 54(9): 69-72.
[5]	彭力,强晔,赵蕙琛,陈诗鸿,姚伟东,刘元涛. 2型糖尿病患者应用西格列汀的短期疗效及影响因素[J]. 山东大学学报（医学版）, 2016, 54(8): 60-63.
[6]	韩康康,崔立伟,彭程,薛玉文,肖伟. 多浆膜腔积液、Warburg效应——弥漫性大B细胞淋巴瘤1例报告并文献复习[J]. 山东大学学报（医学版）, 2016, 54(7): 80-87.
[7]	林栋,管庆波. 2型糖尿病男性患者血清睾酮水平低下对非酒精性脂肪肝的影响[J]. 山东大学学报（医学版）, 2016, 54(7): 33-37.
[8]	臧丽娇,仇杰,庄根苗,安丽. 血清S100B蛋白、神经元特异性烯醇化酶与新生儿低血糖脑损伤的相关性[J]. 山东大学学报（医学版）, 2016, 54(4): 51-54.
[9]	木哈达斯·吐尔逊依明,帕它木·莫合买提,托兰古丽·买买提库尔班. CDKAL1(rs10946398 C/A)基因多态性与2型糖尿病易感性关系Meta分析[J]. 山东大学学报（医学版）, 2016, 54(2): 75-85.
[10]	于宁,高燕燕,咸玉欣,牛佳鹏,李莉,王静,曹彩霞. 艾塞那肽对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪含量及血清chemerin水平的影响[J]. 山东大学学报（医学版）, 2016, 54(11): 51-55.
[11]	张莉,朱惠明,王艳梅,江堤,孙贤久,乐有林. 2型糖尿病患者腹胀与小肠细菌过度生长的关系[J]. 山东大学学报（医学版）, 2016, 54(1): 45-47.
[12]	刘言训, 刘佳, 张涛, 王璐, 薛付忠, 王萍. 基于纵向监测队列的2型糖尿病与甲状腺结节的关联性[J]. 山东大学学报（医学版）, 2015, 53(8): 83-86.
[13]	周冬, 常红, 孙若鹏. 丙酮酸钠对新生鼠低血糖脑损伤的神经保护作用[J]. 山东大学学报（医学版）, 2015, 53(4): 37-42.
[14]	胡芳志, 张正军, 耿厚法, 梁秋华, 孙琳. 2型糖尿病患者尿微量白蛋白与脑组织代谢物变化的关系[J]. 山东大学学报（医学版）, 2015, 53(2): 43-47.
[15]	李方. 可溶性晚期糖基化终末产物受体及其基因多态性与2型糖尿病的易感性分析[J]. 山东大学学报（医学版）, 2015, 53(12): 57-61.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed